Analysis on the detection and antibiotic resistance of extended-spectrum β-lactamases-producing Klebsiella pneumoniae and Escherichia coliisolated from patients in Intensive Care Unit
10.3760/cma.j.issn.1008-6315.2011.06.004
- VernacularTitle:ICU内超广谱β-内酰胺酶肺炎克雷伯菌和大肠埃希菌的检测及耐药性分析
- Author:
Wei GAO
;
Zhimin LIU
;
Xiaoyi LI
;
Jin QIN
- Publication Type:Journal Article
- Keywords:
ICU;
Extended-spectrum β-lactamases;
Klebsiella pneumoniae;
Escherichia coli;
Drug resistance
- From:
Clinical Medicine of China
2011;27(6):572-575
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyse the detection rates and antibiotic resistance of extended-spectrum β-lactamases (ESBLs) producing Klebsiella pneumonia and Escherichia coli in Intensive Care Unit (ICU) and to guide the clinical administration of treatment Methods Klebsiella pneumonia and Escherichia coli collected from clinical samples from January 2008 to December 2010 were tested by Phenotypic Confirmatory Test and confirmed by the method advised by NCCLs and drug-sensitivity was tested with K-B. Results Among the isolated 90 samples,49 strains were considered ESBLs-producing bacteria (54.4%) .with 52. 5% (31/59)of Klebsiella pneumonia and 58. 1% (18/31) of Escherichia coli respectively; with the specimens of respiratory system having the highest rate of 75. 5% (37/49). ESBLs producing bacteria were highly resistant to penicillins and cephalosporins, multi drug resistant to aminoglycosides and quinolones; low to piperacillin/tazobactam,cefoperazone/sulbactam,cefoxitin and amikacin; and all sensitive to imipenem. When compared to non-ESBLs producing strains, the rates of antibiotic resistance of the producing ESBLs strains were significantly higher. Conclusion The test results showed that the isolation rates of ESBLs-producing Klebsiella pneumoniae and Escherichia coli in ICU were high,which had high resistance to most antimicrobial agents,and the resistance was multiple. Imipenem could be the best choice to control the infection due to ESBLs-producing organisms. Timely detection of ESBLs producing bacteria and drug resistance is essential to guide clinical antibiotic using in ICU.
